Commentary
Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach
Andreas Laupacis, J. Michael Paterson, Muhammad Mamdani, Alaa Rostom and Geoffrey M. Anderson
CMAJ November 25, 2003 169 (11) 1167-1170;
Andreas Laupacis
J. Michael Paterson
Muhammad Mamdani
Alaa Rostom
Data supplements
Online Appendix
Files in this Data Supplement:
Related Articles
- Wright, J. M. (2003). Why don't we initiate more large simple randomized controlled trials?. CMAJ, 169(11), 1170-1171. Accessed April 23, 2024. Retrieved from http://www.cmaj.ca/content/169/11/1170.
In this issue
Article tools
Respond to this article
Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach
Andreas Laupacis, J. Michael Paterson, Muhammad Mamdani, Alaa Rostom, Geoffrey M. Anderson
CMAJ Nov 2003, 169 (11) 1167-1170;
Related Articles
Cited By...
- Using Pharmacoepidemiology To Inform Drug Coverage Policy: Initial Lessons From A Two-Province Collaborative
- Patients beware
- Le Vioxx : lecons pour Sante Canada et la FDA
- Vioxx: lessons for Health Canada and the FDA
- Reporting process of randomized controlled trials
- Antidepressants and adverse effects in young patients: uncovering the evidence
- Why don't we initiate more large simple randomized controlled trials?